Abstract 215P
Background
Introduction: About 2-3% of all cancers are renal cell carcinoma (RCC). Nephrectomy is the main treatment. The decision among radical and partial nephrectomy often relies on the tumor size diagnosed by CT scan. It is thus justified to investigate the variation between the radiologic and pathologic size of the tumor and its implications on the management of renal cell carcinoma. Aim: To assess the variation between the radiologic tumor size (RTS) of localized renal cell cancer as measured by Computed tomography (CT) preoperatively and the pathologic tumor size (PTS) as determined from surgical specimen postoperatively.
Methods
The records of 240 patients who underwent nephrectomy due to RCC were taken from the Urology Department of Trivandrum Medical College, Kerala, India. The difference of means for the tumor size on Computed Tomography (CT) scan/ the radiologic tumor size (RTS) and pathologic tumor size (PTS) was calculated using paired T test; the difference was also categorised in terms of sex, type of RCC, type of nephrectomy and T staging. A p value of < 0.05 was considered statistically significant.
Results
The mean age of cases included was 54.82 years (22-78 years) (SD 10.991). The mean RTS was larger than PTS (5.22 ± 2.15 vs. 4.98 ± 2.04 cm, p = <0.001) with a discrepancy of 0.24 cm. The difference among means was found significant for both males and females; significant among clear cell RCC and non - clear cell RCC; and significant for radical neohrectomy but not for partial nephrectomy. Overall 41 of the 240 tumors were down-staged while another 5 up-staged.
Table: 215P Characteristics of the 240 patients with localized renal cell carcinoma
Number of patients | 240 | |
Average age (years) | 54.82 (SD 10.991) | |
Gender- | ||
Male | 159 (66.2%) | |
Female | 81 (33.8%) | |
Histopathologic type- | ||
Clear Cell Carcinoma | 198 (82.5%) | |
Total-Non Clear Cell Carcinoma | 42 (17.5%) | |
Papillary | 22 (9.2%) | |
Chromophobe | 7 (2.9%) | |
PNET | 3 (1.2%) | |
Sarcomatoid | 5 (2.1%) | |
Unclassified | 5 (2.1%) | |
Average tumor size- | ||
RTS | 5.22 (SD 2.15) | |
PTS | 4.98 (SD 2.04) | |
Average difference between RTS and PTS- | 0.24 (SD 0.37) | |
Fuhrman grade | ||
I | 10 (4.2%) | |
II | 177 (73.8%) | |
III | 45 (18.8%) | |
IV | 8 (3.3%) | |
T stage- | Radiologic | Pathologic |
T1a | 100 (41.7%) | 121 (50.4%) |
T1b | 102 (42.5%) | 95 (39.6%) |
T2a | 30 (12.5%) | 17 (7.1%) |
T2b | 8 (3.3%) | 7 (2.9%) |
Stage change- | ||
Down-staged | 41 (17.1%) | |
Up-staged | 5 (2.1%) | |
Total | 46 (19.2%) |
Conclusions
There can be a discrepancy between radiologic size and pathologic tumor size in renal cell cancer which bears repercussions for its management. Message: Mangement of renal cell carcinoma should be carefully selected based on the tumor size diagnosed by CT scan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO20 - Can "Superman" have Chronic Myelomonocytic Leukemia?
Presenter: Alexander Luchinin
Session: Poster display session
Resources:
Abstract
YO21 - Sanctuary Site Central Nervous System Relapse-Refractory DLBCL Responding to Nivolumab and Lenalidomide.
Presenter: Irappa Madabhavi
Session: Poster display session
Resources:
Abstract
YO22 - External Auditory Canal Mass: A Case Series of Squamous Cell Carcinoma
Presenter: Mel Valerie Cruz-Ordinario
Session: Poster display session
Resources:
Abstract
YO23 - Soft tissue Giant cell tumor presented as Nasopharyngeal mass: A case report
Presenter: Emmelyn Buenacosa-Nepucpan
Session: Poster display session
Resources:
Abstract
YO25 - Hyperprogression after pembrolizumab in recurrent oropharyngeal cancer and the use of nab-paclitaxel as salvage treatment- A case report.
Presenter: Izzati Rosli
Session: Poster display session
Resources:
Abstract
YO26 - Exacerbation of radiation necrosis around the radiotherapy-pretreated brain metastases site after immune checkpoint inhibitors.
Presenter: Minako Nishio
Session: Poster display session
Resources:
Abstract
YO27 - Comparative Study Of 20Gray/5Fraction And 30Gray/10 Fraction Whole Brain Radiation In Brain Metastasis
Presenter: Pradip Bhandari
Session: Poster display session
Resources:
Abstract
YO28P - The response to anaplastic lymphoma kinase (ALK) inhibitor in metastatic anaplastic thyroid carcinoma (ATC)
Presenter: Nur Faizah Ab Muin
Session: Poster display session
Resources:
Abstract
YO29 - Acute kidney injury secondary to bilateral renal artery tumor thrombosis in a case of posterior mediastinal undifferentiated sarcoma: case report
Presenter: Ritsu Ibusuki
Session: Poster display session
Resources:
Abstract
YO30 - Follicular dendritic cell sarcoma of the tonsil- a multimodality approach
Presenter: Rich Ericson King
Session: Poster display session
Resources:
Abstract